Copenhagen and Oslo, 4th April 2012, 2012-04-04 17:27 CEST (GLOBE NEWSWIRE) -- Affitech has today received a major shareholder notification from Trans Nova Investments Ltd. Here Trans Nova Investments Ltd. in accordance with Section 29 of the Danish Securities Trading Act gives notice that Trans Nova Investments Limited’s holding of shares and voting rights in Affitech A/S has, as of 4th April 2012 (the settlement date for Trans Nova s public purchase offer to the shareholders of Affitech) been increased from 195,140,258 voting rights/shares of nominal value DKK 0.50 each (corresponding to 40,01% of Affitech A/S voting rights/share capital) to 347,559,802 voting rights/shares of nominal value DKK 0.50 each (corresponding to 71,26% of Affitech A/S voting rights/share capital).
About Affitech
Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.
contact
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com